Updates

  1. 137 new fund letters and reports, each with its own page: Kayne Anderson Rudnick (48 market briefings, KayneCast episodes and TV commentaries), Shelton Capital Management (48 shareholder reports and a commentary), Lakehouse Capital (10 Small Companies Fund letters), Smead (5 newsletters), RIT Capital Partners (5 monthly commentaries), Kovitz, Legal & General, Generation, Hosking, Marram, Munro, Oldfield and others.
  2. 200 new fund letters and reports, each with its own page: Spheria (41 monthly reports), Peapack Private (41 weekly recaps and planning newsletters), Fort Washington (23), Polen Capital (15), Aristotle Pacific (14), Riverwater (13), Chou (10), Apollo Asia Fund (8, back to 1998), Personal Asset Trust, Rockwood Strategic, J Capital Research, I/O Fund, Penn Davis McFarland, Pomona and others.
  3. Investor pages have one Investments tab with shares, changes, % owned, class, market cap and Market cap and Status filters, a Funds tab listing each fund the firm runs, and assets under management from Form ADV. The Investors table shows AUM and current investments, and its search finds investors by what they hold.
  4. Filters, search and sort stay as you left them when you come back to a section. Person cards look like book cards. Company pages name their Investors tab Ownership. Kind and Sector filters use four kinds and GICS sectors with industries. Dead links left the Links tabs.
  5. 190 more investors from fiscal.ai's list, with their sites, letters, partners and 13F holdings; 556 more partner descriptions. Experts now lists only people.
  6. Fund letters lists 144 new documents from 23 firms, each with its own page: a summary, key insights and quotes. Among them: 37 BlackRock articles, 21 Value Partners monthly notes, eight Baron Capital letters, six Stone Sentinel letters to partners, seven Value Line portfolio manager Q&As, BNY's 2026 earnings releases and Starboard Value's 2026 conference presentations.
  7. 584 more investors, with their websites, 6,776 letters from their own sites, 1,385 partners with pages and the 13F holdings of 213 firms. New letters arrive daily from 290 more archives.
  8. Media and Companies filter by GICS sector and industry group, taken from the companies an episode or page names. 1,860 more company pages show a logo, the SEC's list included.
  9. The home page counts what the platform holds and lists features such as the document reader, the player and saved marks. Settings sits at the foot of the rail. Book cards are a quarter wider, so rows hold fewer. Companies drops the Named in filter, and the Role list in your account runs A to Z.
  10. Investor pages of 13 firms show their newsroom's latest posts. New 13F filings are read as the SEC publishes them.
  11. Investor pages have an Investments tab: 13,975 holdings for 105 investors, from their 13F filings with the SEC and their own portfolio pages, with status and sector. 7,338 more companies have a page of their own.
  12. A podcast or YouTube episode keeps playing while you move around the site, in a bar with skip, speed and volume. Media tables show each episode's length and description.
  13. Press releases come from each company's own newsroom (167 companies); SEC filings sit on the Filings tab. Tickers name their exchange, and a company's Experts tab includes guests whose episode description names it.
  14. Letter types now include Market commentary, Fact sheet, Interim report, Annual report, Proxy circular and Governance document. The reader opens over the whole window.
  15. Partners of investment firms have 2,836 appearances and 580 pieces of writing on their pages; Derek Sivers's page lists every book he rates, with his rating.
  16. Fund letters lists three Akre Focus shareholder reports: the ETF's annual report for the year to July 2026, its semi-annual report to January 2026 and the fund's semi-annual report to January 2025, each with its own page: a summary, key insights and quotes.
  17. 837 partners of 73 investment firms now have their own pages, with title, description, photograph and social accounts; Andreessen Horowitz partners' pages also list their writing on a16z.com.
  18. Company pages have a Press releases tab: 8,229 releases for 203 companies, from SEC filings and company newsrooms. Companies filter by For-profit or Non-profit. Own media is a table with filters. Media filters by sector and industry. Publication pages link their publisher in the description.
  19. The Unilever page's Letters tab shows what each fund letter says about Unilever, word for word with its page, and whether the letter is bullish, bearish, mixed or neutral. Filter by sentiment, and see 10 letters at a time.
  20. 492 more fund letters and 3,183 more articles show the day they were published, read from each letter's first page or each article's own page.
  21. The PDF reader has a search box: type words to see every match in the document and step through them. About 540 letters that were web pages, among them Oakmark's commentaries, Bill Miller's letters and Howard Marks's memos, now open in the reader.
  22. Person pages: recommendations open with tier 1 books; one button per organisation; transcripts sit on their episodes; the books on 129 reading lists joined the Recommends tabs.
  23. Companies lists every company with a ticker on the SEC's list, with a Source filter. A quote on a company page opens the letter at that page with the words marked. A company's Media tab lists only episodes that name it, and a new Own media tab lists its podcasts, publications and YouTube channel. Show pages link their publisher. A page opened from a table no longer shows that table's filters beside it.
  24. Company, investor and person pages show more of their social accounts: Facebook, TikTok, Bluesky, Medium, GitHub, Discord and podcast shows. Investor pages list every partner the firm's own team page names: 965 people across 73 investors, 98 for Andreessen Horowitz.
  25. About 170 more letters and papers open in the reader: Mohnish Pabrai's letters and transcripts from his site's new folder, and free copies of papers by Asness, Harvey, Altman, Lo and others from their own or their schools' sites.
  26. Every company a fund letter names has a page, with the letters and quotes that name it: 47 new pages, among them Atom Computing, Hugging Face, Rolls-Royce Holdings and Westinghouse Electric. Company pages have a Quotes tab.
  27. A person's Writing tab has a Type column and filter (Article, Essay, Transcript, Speech, Foreword, Interview and the rest), and Publication names only the publication that published each piece.
  28. Fund letters opens on the newest published letter, and a letter or paper found by search opens its own page here instead of the publisher's site.
  29. A letter or paper with a copy on the site opens its PDF over its page, with a button to open it in a new tab. Select text to highlight or underline it; signed-in readers keep their marks in their account. Each quote opens the PDF at its page with its words marked, and a Source link leads to the publisher's original.
  30. Fund letters lists 61 more documents, each with its own page: Fairfax's 2025 and 2026 interim reports, proxy circulars and 2025 annual report (with their French editions), 26 Charlie Munger meeting transcripts, talks and essays, Third Point's 2026 monthly reports and Malibu Life's interim results, and a Seth Klarman interview. Papers adds Richard Thaler's two 2020 editorials on nudges.
  31. Fund letters lists Lux Capital's letters for Q2 and Q3 2026, by Josh Wolfe, each with its own page: a summary, key insights and quotes.
  32. Fund letters lists Brookfield's letter to shareholders for Q3 2026, by Bruce Flatt, with its own page: a summary, key insights and quotes.
  33. Fund letters lists Howard Marks's memo of 11 November 2026, A Layman Thinks About AI, with its own page: a summary, key insights and quotes.
  34. Fund letters lists 118 more letters, each with its own page: 44 weekly commentaries by Jeremy Siegel from 2026, 31 issues of Van Tharp's newsletter from 2018, 23 Pabrai Investment Funds letters from 2021 to Q3 2026, 13 Efficient Frontier essays by William Bernstein, Oakmark's three 3Q 2026 commentaries, two Lindsell Train reports, a John Hussman comment and Third Point's Q3 2026 letter.
  35. 2,027 more books carry a one-line description in the Books table and on their pages; 7,067 of 7,715 have one, every tier 1, 2 and 3 book among them.
  36. Fund letters lists 187 more letters from 19 firms, among them Permanent Equity, Social Capital, Lux Capital, Square Peg, Bestinver, Cobas, Sequoia Fund, Marketfield and EquityCompass; each shows on its investor's page and has a page of its own.
  37. 2,928 more books carry a one-line description in the Books table and on their pages, so every tier 1, 2 and 3 book has one; 5,040 in all.
  38. Every publication on Newsletters has its own page: its writing, its writers, its staff and who recommends it. Investor pages have a Management tab; a company's Experts tab now leaves out its own people, who list under Management. Tabs on a phone move sideways only.
  39. Every fund letter and research paper has its own page: the thesis, the PDF, the companies and books it names, and for 176 letters and 24 papers so far a summary, key insights and quotes with their page.
  40. 99 books that no page listed now sit under their topics in Books, among them Caste, American Prometheus and Pale Blue Dot.
  41. Newsletters lists every newspaper, magazine, investment newsletter, journal and blog the reference holds, 442 in all, with the people who write there. The search box keeps your last 20 searches. You can create an account.
  42. 283 books that fund managers recommend in their letters are on the shelf, each with the letter's own words and page; investor pages have a Recommends tab.
  43. Person, company, investor and show pages link their own accounts on X, Threads, Instagram, LinkedIn, YouTube and Substack: 275 people, 552 companies and organisations, 88 investors and 478 shows.
  44. 716 more book recommendations name their source: the person's own reading list, letter, blog post, speech or interview, or an article that reports it. 232 of them quote the person's own words about the book, on the book card and on the book's page.
  45. Every US-listed company has a page with its SEC filings. Company pages list their experts and their management, past and present. Fund managers sit under Investors. Each show has a page of its episodes, and an episode page names its guests and hosts. Biographies lists groups, then people. Breadcrumbs show where a page sits.
  46. Media lists every podcast episode, video, interview and talk, over 10,000, by person, company, publisher and event; each filter searches its own choices. Books opens on its table, then Browse, then Authors and Recommenders. A filter's count no longer covers its arrow.
  47. A book that no company, country or subject page lists shows its topics under Where it sits in the reference. On a phone, a page's tabs scroll sideways only. Descriptions read the same on every page. See them in the Experts tab lists every expert the page names.
  48. Every podcast episode, video and interview has its own page with a video or audio player and a link to the source. Investor pages show each company's sector and market cap; firms such as Berkshire Hathaway have one page that holds their letters and their company tabs. Letters tabs filter by company and search the theses. Companies filter by Public, Private and Defunct and link each company's website.
  49. Every tab, view and search has its own address, such as /books/table/asset or /letters/companies, so Back works and a link opens the same place. Page addresses no longer end in .html. Fund letters, Investors, Companies and Papers load about a fifth of the data they did.
  50. Fund letters has a Companies tab: every company the letters name, with its market cap, sector, country, and how many letters and investors name it. Investor pages link each investor's website. Lists in table cells end with “… and N more” at every width.
  51. 1,120 more book summaries; descriptions for 373 papers; pages for 137 more companies, each with the fund letters that discuss it; 215 official photographs; search has its own page.
  52. 411 more books have a summary; person pages list 930 more of the books they wrote; 147 people show their official photograph.
  53. Every investor has a page with its letters and the companies they discuss; company pages list the investors whose letters name them.
  54. A Companies section at the top of the rail lists every company the books, experts and fund letters name.
  55. Person pages list letters, writing, profiles and links as sortable tables with filters, and show each person's companies as links; Fund letters show each letter's description in its own column.
  56. Experts show a checked job title and a short description of each person; 30 more people have photographs.
  57. Every company, fund, university and publication the experts work for has a page listing the people there.
  58. Fund letters show each letter's thesis and filter by it; 225 person pages list the essays, columns and newsletter issues the person wrote.
  59. Person pages list every essay and newsletter issue a person wrote, and their own books as a table in List view.
  60. Recommends shows the five largest kinds of book and the rest under More; browse pictures load sooner.
  61. Podcasts and talks link the original episode, filter by Audio and video or Press, and list each publisher once.
  62. Pages are wider, Recommends has List and Grid, and a filter clicked again turns off.
  63. Book cards sit in a ruled grid with Open Library and Goodreads links and each book's one-line note.
  64. Funds is now Investors; each investor's styles are buttons that filter the table.
  65. Podcasts and talks on a person's page filter by year and publisher and show as a list or a grid of pictures.
  66. Quotes show only people's own words: 472 summaries written by list sites are gone.
  67. Country pages open from Browse again, and every link on the shelf lands on a page.
  68. Subject and person pages show their sections as tabs, and each book appears once on a person's page.
  69. Book cards show the quote, who said it and the source; grids show five cards to a row.
  70. On a phone, a menu holds the sections, search, Updates, Feedback and dark mode.
  71. Feedback takes a screenshot of the page with no browser prompt, opens a screenshot full size when you click it, and clears itself once sent.
  72. Book cards are centred, search names the topic each book sits in, and any text cut short shows whole on hover.
  73. Search groups its results by kind: people, companies, geographies, subjects, topics, books, funds, fund letters and papers.
  74. The Books table lists who recommended each book by name, and the browser tab names the section you are in.
  75. Feedback can take a screenshot of the page, or one you paste or choose, and opens in the corner beside Updates.
  76. Each rail button reopens its section where you left it, and Browse, Table and People show on every book and subject page.
  77. Filters grey out choices that hold nothing instead of hiding them, and Books › People filters by authors or recommenders.
  78. Feedback takes a subject line and up to three screenshots.
  79. Biographies are grouped by the person they are about: 41 new pages, from Abraham Lincoln to Lee Kuan Yew.
  80. Sport splits into 23 sports, and Religion into one topic per faith.
  81. Book lists show as cards: the cover, one recommendation quote and every recommender by name.
  82. Seventeen subjects that had two or three pages under different names now have one page each.
  83. Every page lists its Experts as authors and recommenders, with a link to them on the Experts tab.
  84. Economics, Financial history, Financial panics and Accounting are subjects of their own, with one page per financial crisis.
  85. Book, person and subject pages open inside the app, so the tabs stay in view.
  86. 996 more book covers, and photographs or logos for 227 more people and companies.
  87. Books › Browse shows every subject as cards, and the rail holds Fund letters, Papers, Experts, Books and Funds.
  88. Every topic over 150 books splits into narrower topics, each with a page of its own.

Send feedback

What is it?
Screenshots, up to 3 (optional)
or paste one with Ctrl+V

We use your email only to reply to you.

Perceptive Advisors

Asset ManagerHealthcare

Utilizing our in-depth understanding of the bio-medical landscape, we look for answers, for efficacy, for impact as we explore innovative healthcare technologies and potential investment opportunities.

AUM: $11.8B · Form ADV, 13 Jul 2026

i
Praxis Precision Medicines, Inc.Nasdaq: PRAXCurrentPharmaceutical PreparationsCOM NEW2,024,781-11,205-0.6%7.24%$590M-$92M10.27%$8.7BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Amylyx Pharmaceuticals, Inc.Nasdaq: AMLXCurrentPharmaceutical PreparationsCOM10,573,735+2,238,853+26.9%8.22%$308M+$158M5.36%$3.4BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Spyre Therapeutics, Inc.Nasdaq: SYRECurrentPharmaceutical PreparationsCOM NEW3,280,943-1,038,553-24.0%3.45%$292M-$91M5.09%$9.3BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
ModernaNasdaq: MRNACurrentBiological Products, (No Diagnostic Substances)COM+285.0%$270M+$200M4.70%$80.7BQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Celcuity Inc.Nasdaq: CELCCurrentServices-Medical LaboratoriesCOM3,179,794-17,406-0.5%6.47%$265M-$85M4.61%$2.8BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
RHYTHM PHARMACEUTICALS, INC.Nasdaq: RYTMCurrentPharmaceutical PreparationsCOM2,532,556-53,739-2.1%3.65%$241M-$46M4.20%$8.1BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Roivant Sciences Ltd.Nasdaq: ROIVCurrentPharmaceutical PreparationsSHS6,510,961-1,574,500-19.5%0.90%$238M-$48M4.15%$28.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Relay Therapeutics, Inc.Nasdaq: RLAYCurrentBiological Products, (No Diagnostic Substances)COM12,730,336-1,375,851-9.8%5.76%$230M-$34M4.00%$3.5BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Ascendis Pharma A/SNasdaq: ASNDCurrentPharmaceutical PreparationsORD SHS971,521-192,200-16.5%$221M-$89M3.86%$16.8BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Travere Therapeutics, Inc.Nasdaq: TVTXCurrentPharmaceutical PreparationsCOM3,542,913-209,661-5.6%3.69%$209M-$5M3.63%$4.6BQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Freenome, Inc.Nasdaq: FRNMCurrentServices-Medical LaboratoriesCOMMON STOCK12,606,053+12,606,053New11.31%$199M+$199M3.46%Q3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Edgewise Therapeutics, Inc.Nasdaq: EWTXCurrentPharmaceutical PreparationsCOM4,138,282-235,692-5.4%3.78%$168M-$10M2.93%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Inhibrx Biosciences, Inc.Nasdaq: INBXCurrentBiological Products, (No Diagnostic Substances)COM1,292,463-5,300-0.4%8.75%$129M+$6M2.25%$1.1BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Nurix Therapeutics, Inc.Nasdaq: NRIXCurrentPharmaceutical PreparationsCOM5,371,629+1,051,207+24.3%4.92%$127M+$23M2.22%$1.5BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Kardigan, Inc.Nasdaq: KARDCurrentPharmaceutical PreparationsCOM8,200,66200.0%8.76%$121M-$75M2.11%$1.2BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Meiragtx Hldgs PLCCurrentCOM10,786,65800.0%$119M-$27M2.07%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Protagonist Therapeutics, IncNasdaq: PTGXCurrentPharmaceutical PreparationsCOM836,579-145,300-14.8%1.28%$118M-$2M2.05%$8.1BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Immatics N.V.Nasdaq: IMTXCurrentBiological Products, (No Diagnostic Substances)SHS11,246,516+863,060+8.3%$99M-$6M1.72%$906MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Zymeworks Inc.Nasdaq: ZYMECurrentPharmaceutical PreparationsCOM3,545,501-637,452-15.2%5.14%$94M-$15M1.64%$1.9BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Revolution Medicines, Inc.Nasdaq: RVMDCurrentBiological Products, (No Diagnostic Substances)COM683,100-94,500-12.2%0.32%$92M-$9M1.60%$34.5BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Oruka Therapeutics, Inc.Nasdaq: ORKACurrentPharmaceutical PreparationsCOM1,072,363-272,700-20.3%1.58%$89M-$39M1.56%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Solid Biosciences Inc.Nasdaq: SLDBCurrentBiological Products, (No Diagnostic Substances)COM NEW11,906,64600.0%10.67%$86M-$33M1.50%$719MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
BIOCRYST PHARMACEUTICALS INCNasdaq: BCRXCurrentBiological Products, (No Diagnostic Substances)COM10,301,888-7,000-0.1%4.00%$86M-$17M1.49%$1.9BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Avalyn Pharma Inc.Nasdaq: AVLNCurrentPharmaceutical PreparationsCOM SHS2,675,29600.0%6.03%$76M-$12M1.33%$1.3BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
SELLAS Life Sciences Group, Inc.Nasdaq: SLSCurrentPharmaceutical PreparationsCOM NEW+205.8%$68M+$46M1.18%$3.0BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Tango Therapeutics, Inc.Nasdaq: TNGXCurrentPharmaceutical PreparationsCOM2,693,000-684,000-20.3%1.59%$67M-$38M1.17%$3.8BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
WatersNYSE: WATCurrentLaboratory Analytical InstrumentsCOM135,000+135,000New0.14%$59M+$59M1.03%$86.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
REPLIGEN CORPNasdaq: RGENCurrentBiological Products, (No Diagnostic Substances)COM272,456+24,244+9.8%0.43%$52M+$19M0.91%$10.9BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
ARTIVION, INC.NYSE: AORTCurrentSurgical & Medical Instruments & ApparatusCOM2,112,290+375,000+21.6%4.33%$48M+$9M0.84%$904MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Alto Neuroscience, Inc.NYSE: ANROCurrentPharmaceutical PreparationsCOM SHS1,760,950+151,057+9.4%4.39%$45M+$2M0.78%$1.1BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Opus Genetics, Inc.Nasdaq: IRDCurrentPharmaceutical PreparationsCOM9,000,000+9,000,000New9.31%$44M+$44M0.76%$394MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Lakefront Biotherapeutics NVNasdaq: LKFTCurrentPharmaceutical PreparationsSPON ADR1,242,404+1,242,404New$37M+$37M0.64%$2.2BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
ABBOTT LABORATORIESNYSE: ABTCurrentPharmaceutical PreparationsCOM345,225+345,225New0.02%$34M+$34M0.59%$180BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
BlossomHill Therapeutics, Inc.Nasdaq: BLSMCurrentPharmaceutical PreparationsCOM1,812,193+1,812,193New5.70%$34M+$34M0.59%$458MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Spdr Series TrustCurrentFundST STR SP BIOT-33.6%$32M-$16M0.55%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Orchestra BioMed Holdings, Inc.Nasdaq: OBIOCurrentSurgical & Medical Instruments & ApparatusCOM5,037,606-300-0.0%6.40%$31M+$10M0.55%$551MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Corvus Pharmaceuticals, Inc.Nasdaq: CRVSCurrentPharmaceutical PreparationsCOM2,510,441-157,000-5.9%2.98%$29M-$11M0.50%$844MQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Anteris Technologies Global Corp.Nasdaq: AVRCurrentOrthopedic, Prosthetic & Surgical Appliances & SuppliesCOM3,425,47600.0%3.51%$27M-$7M0.46%Q3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Adlai Nortye Group Ltd.Nasdaq: ANLCurrentPharmaceutical PreparationsSPONSORED ADS1,660,502-132,688-7.4%$27M+$6M0.46%$583MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
MiniMed Group, Inc.Nasdaq: MMEDCurrentSurgical & Medical Instruments & ApparatusCOM1,320,000+1,320,000New0.47%$26M+$26M0.45%$4.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
CytomX Therapeutics, Inc.Nasdaq: CTMXCurrentPharmaceutical PreparationsCOM9,268,061-1,171,124-11.2%4.25%$25M-$14M0.44%$447MQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Rapport Therapeutics, Inc.Nasdaq: RAPPCurrentPharmaceutical PreparationsCOM724,342-49,000-6.3%1.22%$24M-$8M0.42%$1.4BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Septerna, Inc.Nasdaq: SEPNCurrentPharmaceutical PreparationsCOM567,479+567,479New1.19%$22M+$22M0.39%$1.9BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
X4 Pharmaceuticals, IncNasdaq: XFORCurrentBiological Products, (No Diagnostic Substances)COM NEW7,350,491-583,000-7.3%7.20%$21M-$16M0.37%$302MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Enliven Therapeutics, Inc.Nasdaq: ELVNCurrentPharmaceutical PreparationsCOM462,506+462,506New0.63%$21M+$21M0.37%$3.4BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
SAB Biotherapeutics, Inc.Nasdaq: SABSCurrentBiological Products, (No Diagnostic Substances)COM NEW6,627,50100.0%7.36%$21M-$5M0.37%$262MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Dyne Therapeutics, Inc.Nasdaq: DYNCurrentPharmaceutical PreparationsCOM1,265,362-1,423,873-52.9%0.68%$20M-$39M0.36%$3.0BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Evolus, Inc.Nasdaq: EOLSCurrentPharmaceutical PreparationsCOM2,459,28500.0%3.72%$20M+$3M0.34%$463MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Yarrow Bioscience, Inc.Nasdaq: YARWCurrentPharmaceutical PreparationsCOM813,098+813,098New5.34%$18M+$18M0.32%$217MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Immunovant, Inc.Nasdaq: IMVTCurrentBiological Products, (No Diagnostic Substances)COM519,345-838,038-61.7%0.25%$18M-$35M0.31%$6.7BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Scribe Therapeutics, Inc.Nasdaq: SCTXCurrentBiological Products, (No Diagnostic Substances)COM920,341+920,341New4.86%$17M+$17M0.30%$250MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Nautilus Biotechnology, Inc.Nasdaq: NAUTCurrentLaboratory Analytical InstrumentsCOM11,564,744-69,467-0.6%9.08%$16M-$5M0.29%$276MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
SUTRO BIOPHARMA, INC.Nasdaq: STROCurrentBiological Products, (No Diagnostic Substances)COM SHS970,846-334,000-25.6%5.85%$16M-$28M0.27%$145MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Newamsterdam Pharma CompanyCurrentORDINARY SHARES-13.9%$15M-$2M0.25%Q3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Surrozen, Inc./DENasdaq: SRZNCurrentBiological Products, (No Diagnostic Substances)COM NEW439,685-230,966-34.4%2.31%$14M+$1M0.25%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
EyePoint, Inc.Nasdaq: EYPTCurrentLaboratory Analytical InstrumentsCOM NEW-51.7%$14M-$15M0.24%$30MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
GRAILNasdaq: GRALCurrentServices-Medical LaboratoriesCOM96,911+96,911New0.22%$14M+$14M0.24%$4.5BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
DBV Technologies S.A.Nasdaq: DBVTCurrentBiological Products, (No Diagnostic Substances)SPONSORED ADS1,136,534-516,816-31.3%0.36%$13M-$14M0.23%$592MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
DanaherNYSE: DHRCurrentIndustrial Instruments For Measurement, Display, and ControlCOM60,000-70,000-53.8%0.01%$13M-$11M0.23%$155BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
iRhythm Holdings, Inc.Nasdaq: IRTCCurrentSurgical & Medical Instruments & ApparatusCOM113,766-110,000-49.2%0.34%$13M-$14M0.23%$3.2BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Guardant Health, Inc.Nasdaq: GHCurrentServices-Medical LaboratoriesCOM70,000+28,673+69.4%0.05%$12M+$6M0.22%$19.7BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Invivyd, Inc.Nasdaq: IVVDCurrentBiological Products, (No Diagnostic Substances)COM13,762,637-4,727,999-25.6%4.66%$12M-$4M0.21%$132MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Adaptive Biotechnologies CorpNasdaq: ADPTCurrentBiological Products, (No Diagnostic Substances)COM412,325-805,000-66.1%0.25%$12M-$14M0.21%$4.5BQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Veradermics, IncNYSE: MANECurrentPharmaceutical PreparationsCOMMON STOCK97,000+97,000New0.23%$12M+$12M0.20%$5.2BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Axogen, Inc.Nasdaq: AXGNCurrentElectromedical & Electrotherapeutic ApparatusCOM280,000+32,688+13.2%0.47%$12M+$0.3M0.20%$3.4BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
PALISADE BIO, INC.Nasdaq: PALICurrentBiological Products, (No Diagnostic Substances)COM8,425,06500.0%4.70%$11M-$6M0.20%$166MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
CRESCENT BIOPHARMA, INC.Nasdaq: CBIOCurrentPharmaceutical PreparationsCOM706,942+500,000+241.6%1.82%$10M+$7M0.18%$539MQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Beta Bionics, Inc.Nasdaq: BBNXCurrentSurgical & Medical Instruments & ApparatusCOM538,159-294,785-35.4%0.99%$10M-$3M0.18%$724MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Seaport Therapeutics, Inc.Nasdaq: SPTXCurrentPharmaceutical PreparationsCOMMON STOCK500,00000.0%0.93%$10M-$0.8M0.18%$981MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Entera Bio Ltd.Nasdaq: ENTXCurrentBiological Products, (No Diagnostic Substances)SHS3,431,372+3,431,372New1.97%$10M+$10M0.17%$571MQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Mirum Pharmaceuticals, Inc.Nasdaq: MIRMCurrentPharmaceutical PreparationsCOM115,39100.0%0.18%$10M-$4M0.17%$6.2BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Uniqure NVCurrentSHS402,773+234,773+139.7%$10M+$2M0.17%Q3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
Xeris Biopharma Holdings, Inc.Nasdaq: XERSCurrentPharmaceutical PreparationsCOM933,671+466,658+99.9%0.51%$9M+$5M0.16%$3.0BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Research Alliance Corp IVNasdaq: RACDCurrentBlank ChecksCL A ORD SHS700,000+700,000New$8M+$8M0.14%Q3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
CAPRICOR THERAPEUTICS, INC.Nasdaq: CAPRCurrentPharmaceutical PreparationsCOM NEW850,000-77.7%1.46%$8M-$28M0.14%$438MQ3 202616 Nov 2026Q2 2025Q3 202613F, Q3 2026
Viridian Therapeutics, Inc.\DENasdaq: VRDNCurrentPharmaceutical PreparationsCOM381,452-200,528-34.5%0.34%$8M-$3M0.14%$3.6BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Abivax S.A.Nasdaq: ABVXCurrentPharmaceutical PreparationsSPONSORED ADS74,00000.0%$7M-$3M0.13%$7.1BQ3 202616 Nov 2026Q3 2025Q3 202613F, Q3 2026
enGene Therapeutics Inc.Nasdaq: ENGNCurrentBiological Products, (No Diagnostic Substances)COM3,482,169-1,340,000-27.8%5.20%$7M-$1M0.12%$118MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
BillionToOne, Inc.Nasdaq: BLLNCurrentServices-Medical LaboratoriesCL A65,209-21,603-24.9%$7M-$3M0.12%$4.3BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
AgomAb Therapeutics NVNasdaq: AGMBCurrentBiological Products, (No Diagnostic Substances)SPONSORED ADS600,00000.0%$7M-$1M0.12%$277MQ3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
LeonaBio, Inc.Nasdaq: LONACurrentBiological Products, (No Diagnostic Substances)COM1,859,32200.0%14.22%$7M-$10M0.12%$32MQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
BIOGEN INC.Nasdaq: BIIBCurrentBiological Products, (No Diagnostic Substances)COM28,030-248,143-89.9%0.02%$6M-$53M0.11%$36.5BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
ADARx Pharmaceuticals, Inc.Nasdaq: ADRXCurrentPharmaceutical PreparationsCOM300,000+300,000New0.27%$6M+$6M0.10%$1.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Nuvectis Pharma, Inc.Nasdaq: NVCTCurrentPharmaceutical PreparationsCOM240,000-760,000-76.0%0.70%$5M-$13M0.09%$682MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Olema Pharmaceuticals, Inc.Nasdaq: OLMACurrentPharmaceutical PreparationsCOM575,000+575,000New0.66%$5M+$5M0.09%$626MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
Oculis Holding AGNasdaq: OCSCurrentPharmaceutical PreparationsORDINARY SHARES440,827-368,000-45.5%$4M-$7M0.07%$415MQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
UNITEDHEALTH GROUP INCNYSE: UNHCurrentHospital & Medical Service PlansCOM10,000-106,806-91.4%<0.01%$4M-$45M0.06%$296BQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Mobia Medical, Inc.Nasdaq: MOBICurrentSurgical & Medical Instruments & ApparatusCOMMON STOCK343,654-180,000-34.4%1.03%$3M-$4M0.06%$395MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Biohaven Ltd.NYSE: BHVNCurrentPharmaceutical PreparationsCOMNew$3M+$3M0.05%$2.1BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
Outset Medical, Inc.Nasdaq: OMCurrentElectromedical & Electrotherapeutic ApparatusCOM NEW833,33300.0%4.42%$2M-$1M0.04%$55MQ3 202616 Nov 2026Q1 2025Q3 202613F, Q3 2026
Ceribell, Inc.Nasdaq: CBLLCurrentElectromedical & Electrotherapeutic ApparatusCOM98,779+98,779New0.25%$2M+$2M0.04%$1.0BQ3 202616 Nov 2026Q4 2024Q3 202613F, Q3 2026
Edesa Biotech, Inc.Nasdaq: EDSACurrentPharmaceutical PreparationsCOM NEW563,23900.0%5.84%$2M-$2M0.04%Q3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Braveheart Bio, Inc.Nasdaq: BRVECurrentPharmaceutical PreparationsCOM SHS115,000+115,000New0.13%$2M+$2M0.04%$1.6BQ3 202616 Nov 2026Q3 2026Q3 202613F, Q3 2026
Outlook Therapeutics, Inc.Nasdaq: OTLKCurrentBiological Products, (No Diagnostic Substances)COM3,139,21600.0%1.29%$2M-$3M0.03%$98MQ3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Adagio Med Hldgs IncCurrentCOM9,876,58600.0%$2M-$5M0.03%Q3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
ADMA BIOLOGICS, INC.Nasdaq: ADMACurrentBiological Products, (No Diagnostic Substances)COM113,76500.0%0.05%$1M+$0.2M0.02%$3.0BQ3 202616 Nov 2026Q3 2024Q3 202613F, Q3 2026
KIORA PHARMACEUTICALS INCNasdaq: KPRXCurrentPharmaceutical PreparationsCOM438,47100.0%9.91%$1M-$0.0M0.02%Q3 202616 Nov 2026Q2 2026Q3 202613F, Q3 2026
Medline Inc.Nasdaq: MDLNCurrentSurgical & Medical Instruments & ApparatusCOM CL A28,00000.0%$1.0M-$0.1M0.02%$49.8BQ3 202616 Nov 2026Q4 2025Q3 202613F, Q3 2026
EXAGEN INC.Nasdaq: XGNCurrentServices-Medical LaboratoriesCOM114,89300.0%0.45%$0.9M+$0.4M0.02%Q3 202616 Nov 2026Q1 2026Q3 202613F, Q3 2026
Ascendis Pharma A/S Sponsored ADRExitedSPONSORED ADR0-1,531,421-100.0%-$350MQ2 202614 Aug 2026Q2 2025Q1 202613F, Q1 2026
Centessa Pharmaceuticals PLCExitedSPONSORED ADS0-5,258,903-100.0%-$209MQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Nuvalent IncExitedCOM0-1,580,505-100.0%-$195MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Apogee Therapeutics IncExitedCOM0-1,308,113-100.0%-$174MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Merus N VExitedCOM0-1,353,093-100.0%-$127MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Exact Sciences CorpExitedCOM0-1,200,487-100.0%-$122MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Intra-Cellular Therapies IncExitedCOM0-786,358-100.0%-$104MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
INSMED IncNasdaq: INSMExitedPharmaceutical PreparationsCOM PAR $.010-702,130-100.0%-$101M$31.7BQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
ArcellxExitedCOMMON STOCK0-1,466,071-100.0%-$96MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Amicus TherapeuticsExitedCOM0-6,370,851-100.0%-$91MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Astria Therapeutics IncExitedCOM0-6,485,420-100.0%-$85MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Verona Pharma PLCExitedSPONSORED ADS0-524,088-100.0%-$56MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Akero Therapeutics IncExitedCOM0-1,135,766-100.0%-$54MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
IONIS PHARMACEUTICALS INCNasdaq: IONSExitedPharmaceutical PreparationsCOM0-566,000-100.0%-$45M$4.5BQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
IOVANCE BIOTHERAPEUTICS, INC.Nasdaq: IOVAExitedBiological Products, (No Diagnostic Substances)COM0-12,711,788-100.0%-$42M$3.4BQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Jazz Pharmaceuticals plcNasdaq: JAZZExitedPharmaceutical PreparationsSHS USD0-170,000-100.0%-$41M$15.2BQ3 202616 Nov 2026Q4 2025Q2 202613F, Q2 2026
Sionna Therapeutics, Inc.Nasdaq: SIONExitedPharmaceutical PreparationsCOM0-905,000-100.0%-$40M$134MQ3 202616 Nov 2026Q1 2025Q2 202613F, Q2 2026
Engene Holdings IncExitedCOM0-5,827,506-100.0%-$40MQ2 202614 Aug 2026Q3 2025Q1 202613F, Q1 2026
Day One Biopharmaceuticals IncExitedCOM0-1,755,799-100.0%-$38MQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
Cidara Therapeutics, Inc.ExitedCOM NEW0-165,131-100.0%-$36MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Soleno Therapeutics IncExitedCOM0-430,439-100.0%-$36MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
Disc Medicine, Inc.Nasdaq: IRONExitedPharmaceutical PreparationsCOM0-450,743-100.0%-$36M$3.5BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
ARGENX SENasdaq: ARGXExitedBiological Products, (No Diagnostic Substances)SPONSORED ADR0-59,510-100.0%-$35M$59.2BQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
CORCEPT THERAPEUTICS INCNasdaq: CORTExitedPharmaceutical PreparationsCOM0-398,385-100.0%-$35M$7.1BQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
Penumbra IncNYSE: PENExitedSurgical & Medical Instruments & ApparatusCOM0-110,529-100.0%-$34M$12.6BQ1 202615 May 2026Q4 2024Q4 202513F, Q4 2025
Damora Therapeutics, Inc.Nasdaq: DMRAExitedPharmaceutical PreparationsCOM NEW0-1,223,000-100.0%-$32M$1.5BQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.NYSE: CRLExitedServices-Commercial Physical & Biological ResearchCOM0-140,000-100.0%-$32M$15.7BQ3 202616 Nov 2026Q2 2025Q2 202613F, Q2 2026
Caris Life Sciences, Inc.Nasdaq: CAIExitedServices-Medical LaboratoriesCOM0-1,136,206-100.0%-$31M$5.3BQ1 202615 May 2026Q2 2025Q4 202513F, Q4 2025
Axsome Therapeutics, Inc.Nasdaq: AXSMExitedPharmaceutical PreparationsCOM0-118,450-100.0%-$29M$7.1BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
RAPT TherapeuticsExitedCOM NEW0-825,890-100.0%-$28MQ1 202615 May 2026Q4 2024Q4 202513F, Q4 2025
PALVELLA THERAPEUTICS, INC.Nasdaq: PVLAExitedPharmaceutical PreparationsCOM0-266,287-100.0%-$28M$2.1BQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
BRIGHT MINDS BIOSCIENCES INC.Nasdaq: DRUGExitedPharmaceutical PreparationsCOM NEW0-377,544-100.0%-$28M$204MQ2 202614 Aug 2026Q4 2024Q1 202613F, Q1 2026
Vaxcyte, Inc.Nasdaq: PCVXExitedBiological Products, (No Diagnostic Substances)COM0-706,567-100.0%-$27M$9.2BQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
TENAX THERAPEUTICS, INC.Nasdaq: TENXExitedPharmaceutical PreparationsCOM NEW0-1,700,000-100.0%-$25MQ3 202616 Nov 2026Q4 2025Q2 202613F, Q2 2026
BELITE BIO, INCNasdaq: BLTEExitedPharmaceutical PreparationsSPONSORED ADS0-151,979-100.0%-$24M$6.1BQ2 202614 Aug 2026Q3 2025Q1 202613F, Q1 2026
Kodiak Sciences Inc.Nasdaq: KODExitedBiological Products, (No Diagnostic Substances)COM0-848,900-100.0%-$24M$6.4BQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
PROCEPT BioRobotics CorpNasdaq: PRCTExitedSurgical & Medical Instruments & ApparatusCOM0-290,659-100.0%-$23M$1.5BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Instil Bio, Inc.Nasdaq: TILExitedBiological Products, (No Diagnostic Substances)COM NEW0-345,545-100.0%-$23M$38MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
LivaNova PLCNasdaq: LIVNExitedElectromedical & Electrotherapeutic ApparatusSHS0-429,000-100.0%-$23M$5.1BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Springworks Therapeutics IncExitedCOM0-692,263-100.0%-$22MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Medtronic plcNYSE: MDTExitedElectromedical & Electrotherapeutic ApparatusSHS0-245,332-100.0%-$22M$129BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Aldeyra Therapeutics, Inc.Nasdaq: ALDXExitedPharmaceutical PreparationsCOM0-4,185,632-100.0%-$22M$44MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
Intuitive SurgicalNasdaq: ISRGExitedOrthopedic, Prosthetic & Surgical Appliances & SuppliesCOM NEW0-51,884-100.0%-$21M$138BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Contineum Therapeutics, Inc.Nasdaq: CTNMExitedPharmaceutical PreparationsCL A0-1,255,592-100.0%-$21M$355MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
INSULET CORPNasdaq: PODDExitedSurgical & Medical Instruments & ApparatusCOM0-60,387-100.0%-$19M$9.5BQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
CVS HEALTH CorpNYSE: CVSExitedRetail-Drug Stores and Proprietary StoresCOM0-220,000-100.0%-$17M$102BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Omada Health, Inc.Nasdaq: OMDAExitedServices-Health ServicesCOM0-786,330-100.0%-$17M$775MQ3 202616 Nov 2026Q2 2025Q2 202613F, Q2 2026
GLAUKOS CorpNYSE: GKOSExitedSurgical & Medical Instruments & ApparatusCOM0-140,000-100.0%-$16M$14.1BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Madrigal PharmaceuticalsNasdaq: MDGLExitedPharmaceutical PreparationsCOM0-46,500-100.0%-$15M$9.2BQ2 202514 Aug 2025Q1 2025Q1 202513F, Q1 2025
DexcomNasdaq: DXCMExitedSurgical & Medical Instruments & ApparatusCOM0-225,758-100.0%-$15M$29.9BQ1 202615 May 2026Q1 2025Q4 202513F, Q4 2025
Savara IncNasdaq: SVRAExitedPharmaceutical PreparationsCOM0-2,400,000-100.0%-$14M$1.1BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
ARVINAS, INC.Nasdaq: ARVNExitedPharmaceutical PreparationsCOM0-740,749-100.0%-$14M$441MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
ICONNasdaq: ICLRExitedServices-Commercial Physical & Biological ResearchSHS0-44,353-100.0%-$13M$14.3BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Arcutis Biotherapeutics, Inc.Nasdaq: ARQTExitedPharmaceutical PreparationsCOM0-1,358,500-100.0%-$13M$3.4BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
CG Oncology, Inc.Nasdaq: CGONExitedBiological Products, (No Diagnostic Substances)COM0-419,450-100.0%-$12M$7.3BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Tyra Biosciences, Inc.Nasdaq: TYRAExitedPharmaceutical PreparationsCOM0-511,226-100.0%-$12M$1.4BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Oscar Health, Inc.NYSE: OSCRExitedHospital & Medical Service PlansCL A0-400,000-100.0%-$11M$8.1BQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Acrivon Therapeutics, Inc.Nasdaq: ACRVExitedPharmaceutical PreparationsCOMMON STOCK0-5,360,858-100.0%-$11M$60MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Edwards Lifesciences CorpNYSE: EWExitedOrthopedic, Prosthetic & Surgical Appliances & SuppliesCOM0-145,000-100.0%-$11M$59.7BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
BOSTON SCIENTIFIC CORPNYSE: BSXExitedSurgical & Medical Instruments & ApparatusCOM0-250,000-100.0%-$11M$62.3BQ3 202616 Nov 2026Q1 2025Q2 202613F, Q2 2026
Xencor IncNasdaq: XNCRExitedPharmaceutical PreparationsCOM0-527,671-100.0%-$11M$2.6BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Tarsus PharmaceuticalsNasdaq: TARSExitedBiological Products, (No Diagnostic Substances)COM0-186,662-100.0%-$10M$3.8BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Evommune, Inc.NYSE: EVMNExitedPharmaceutical PreparationsCOM SHS0-448,350-100.0%-$10M$299MQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
Neumora Therapeutics, Inc.Nasdaq: NMRAExitedBiological Products, (No Diagnostic Substances)COM0-5,104,097-100.0%-$10M$65MQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
Cargo Therapeutics IncExitedCOM0-2,431,085-100.0%-$10MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Ultragenyx Pharmaceutical Inc.Nasdaq: RAREExitedPharmaceutical PreparationsCOM0-270,000-100.0%-$10M$1.8BQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
ArriVent BioPharma, Inc.Nasdaq: AVBPExitedPharmaceutical PreparationsCOM0-415,000-100.0%-$10M$582MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Gossamer Bio IncExitedCOM0-3,139,669-100.0%-$10MQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
MapLight Therapeutics, Inc.Nasdaq: MPLTExitedPharmaceutical PreparationsCOM0-550,000-100.0%-$10M$357MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Crinetics Pharmaceuticals IncExitedCOM0-184,525-100.0%-$9MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Natera, Inc.Nasdaq: NTRAExitedServices-Medical LaboratoriesCOM0-34,689-100.0%-$9M$42.0BQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Inari Med IncExitedCOM0-178,797-100.0%-$9MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Xenon Pharmaceuticals Inc.Nasdaq: XENEExitedPharmaceutical PreparationsCOM0-200,791-100.0%-$9M$3.7BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
NEUROCRINE BIOSCIENCES INCNasdaq: NBIXExitedBiological Products, (No Diagnostic Substances)COM0-65,050-100.0%-$9M$15.8BQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Research Alliance Corp IIINasdaq: RACCExitedPharmaceutical PreparationsORD SHS CL A0-750,000-100.0%-$8MQ3 202616 Nov 2026Q2 2026Q2 202613F, Q2 2026
Cullinan Therapeutics, Inc.Nasdaq: CGEMExitedBiological Products, (No Diagnostic Substances)COM0-426,478-100.0%-$8M$589MQ3 202616 Nov 2026Q1 2025Q2 202613F, Q2 2026
Allogene Therapeutics, Inc.Nasdaq: ALLOExitedBiological Products, (No Diagnostic Substances)COM0-2,725,000-100.0%-$8M$231MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Kestra Medical Technologies Ltd.ExitedSHS0-285,000-100.0%-$8MQ1 202615 May 2026Q1 2025Q4 202513F, Q4 2025
Janux Therapeutics, Inc.Nasdaq: JANXExitedPharmaceutical PreparationsCOM0-292,686-100.0%-$7M$630MQ4 202517 Feb 2026Q4 2024Q3 202513F, Q3 2025
Tempus AI, Inc.Nasdaq: TEMExitedServices-Computer Programming, Data Processing, Etc.CL A0-85,000-100.0%-$7M$10.9BQ4 202517 Feb 2026Q3 2025Q3 202513F, Q3 2025
Zenas BioPharma, Inc.Nasdaq: ZBIOExitedPharmaceutical PreparationsCOM0-744,035-100.0%-$6M$1.7BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
DELCATH SYSTEMS, INC.Nasdaq: DCTHExitedSurgical & Medical Instruments & ApparatusCOM NEW0-462,422-100.0%-$6M$669MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Phathom Pharmaceuticals, Inc.Nasdaq: PHATExitedPharmaceutical PreparationsCOM0-532,000-100.0%-$6M$413MQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
Kymera Therapeutics, Inc.Nasdaq: KYMRExitedBiological Products, (No Diagnostic Substances)COM0-69,935-100.0%-$5M$10.2BQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
PepGen Inc.Nasdaq: PEPGExitedPharmaceutical PreparationsCOM0-829,870-100.0%-$5M$370MQ1 202615 May 2026Q3 2024Q4 202513F, Q4 2025
FILANA THERAPEUTICS, INC.Nasdaq: FLNAExitedPharmaceutical PreparationsCOM-100.0%-$5M$28MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
GLOBUS MEDICAL INCNYSE: GMEDExitedSurgical & Medical Instruments & ApparatusCL A0-88,500-100.0%-$5M$9.1BQ3 202514 Nov 2025Q2 2025Q2 202513F, Q2 2025
Tectonic Therapeutic, Inc.Nasdaq: TECXExitedBiological Products, (No Diagnostic Substances)COM-100.0%-$5M$411MQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Heartflow, Inc.Nasdaq: HTFLExitedSurgical & Medical Instruments & ApparatusCOM0-150,000-100.0%-$5M$3.9BQ4 202517 Feb 2026Q3 2025Q3 202513F, Q3 2025
Aquestive Therapeutics, Inc.Nasdaq: AQSTExitedPharmaceutical PreparationsCOM0-747,193-100.0%-$5M$466MQ1 202615 May 2026Q1 2025Q4 202513F, Q4 2025
Cogent BiosciencesNasdaq: COGTExitedPharmaceutical PreparationsCOM0-121,082-100.0%-$5M$4.8BQ3 202616 Nov 2026Q4 2025Q2 202613F, Q2 2026
OnKure Therapeutics, Inc.Nasdaq: OKURExitedPharmaceutical PreparationsCOM CL A0-1,004,439-100.0%-$4M$114MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
Krystal Biotech, Inc.Nasdaq: KRYSExitedBiological Products, (No Diagnostic Substances)COM0-17,500-100.0%-$4M$9.4BQ1 202615 May 2026Q3 2025Q4 202513F, Q4 2025
OCULAR THERAPEUTIX, INCNasdaq: OCULExitedPharmaceutical PreparationsCOM-100.0%-$4M$1.3BQ2 202614 Aug 2026Q3 2024Q1 202613F, Q1 2026
Helix Acquisition Corp IiExitedCL A ORD SHS0-398,000-100.0%-$4MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
VERU INC.Nasdaq: VERUExitedPharmaceutical PreparationsCOM0-6,483,157-100.0%-$4M$36MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Avalo Therapeutics, Inc.Nasdaq: AVTXExitedPharmaceutical PreparationsCOM NEW0-219,813-100.0%-$4M$390MQ3 202616 Nov 2026Q1 2025Q2 202613F, Q2 2026
Inhibikase Therapeutics, Inc.Nasdaq: IKTExitedBiological Products, (No Diagnostic Substances)COM NEW0-2,315,000-100.0%-$4M$182MQ2 202614 Aug 2026Q4 2024Q1 202613F, Q1 2026
PRECISION BIOSCIENCES INCNasdaq: DTILExitedBiological Products, (No Diagnostic Substances)COM NEW0-426,293-100.0%-$4M$264MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Perspective Therapeutics, Inc.NYSE: CATXExitedPharmaceutical PreparationsCOM NEW0-1,190,263-100.0%-$4M$95MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Twist Bioscience CorpNasdaq: TWSTExitedBiological Products, (No Diagnostic Substances)COM0-36,812-100.0%-$4M$7.6BQ3 202616 Nov 2026Q1 2026Q2 202613F, Q2 2026
Lineage Cell Therapeutics, Inc.NYSE: LCTXExitedBiological Products, (No Diagnostic Substances)COM0-7,236,843-100.0%-$4M$207MQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Schrodinger, Inc.Nasdaq: SDGRExitedPharmaceutical PreparationsCOM0-202,400-100.0%-$4M$2.0BQ1 202615 May 2026Q4 2025Q4 202513F, Q4 2025
Scpharmaceuticals IncExitedCOM0-583,142-100.0%-$3MQ4 202517 Feb 2026Q4 2024Q3 202513F, Q3 2025
Apellis Pharmaceuticals IncExitedCOM0-80,956-100.0%-$3MQ2 202614 Aug 2026Q1 2026Q1 202613F, Q1 2026
ImmunityBio, Inc.Nasdaq: IBRXExitedBiological Products, (No Diagnostic Substances)COM0-1,221,734-100.0%-$3M$7.0BQ1 202515 May 2025Q4 2024Q4 202413F, Q4 2024
Viking Therapeutics, Inc.Nasdaq: VKTXExitedPharmaceutical PreparationsCOM0-105,597-100.0%-$3M$3.3BQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
BICYCLE THERAPEUTICS PLCNasdaq: BCYCExitedPharmaceutical PreparationsSPONSORED ADS0-197,108-100.0%-$3M$214MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Absci CorpNasdaq: ABSIExitedServices-Commercial Physical & Biological ResearchCOM0-700,000-100.0%-$3M$1.4BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Pyxis Oncology, Inc.Nasdaq: PYXSExitedPharmaceutical PreparationsCOMMON STOCK0-1,178,307-100.0%-$3M$201MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
BIODESIX INCNasdaq: BDSXExitedServices-Medical LaboratoriesCOM0-108,694-100.0%-$2M$92MQ3 202616 Nov 2026Q3 2024Q2 202613F, Q2 2026
Verrica Pharmaceuticals Inc.Nasdaq: VRCAExitedPharmaceutical PreparationsCOM0-3,249,669-100.0%-$2M$50MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
ARS Pharmaceuticals, Inc.Nasdaq: SPRYExitedPharmaceutical PreparationsCOM-100.0%-$2M$338MQ4 202517 Feb 2026Q3 2025Q3 202513F, Q3 2025
Mereo BioPharma Group plcNasdaq: MREOExitedPharmaceutical PreparationsSPON ADS0-876,961-100.0%-$2M$44MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
TRINITY BIOTECH PLCNasdaq: TRIBExitedIn Vitro & In Vivo Diagnostic SubstancesSPONS ADR NEW0-1,790,000-100.0%-$2M$4MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
enVVeno Medical CorpNasdaq: NVNOExitedSurgical & Medical Instruments & ApparatusCOM0-1,759,035-100.0%-$2M$4MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Structure Therapeutics Inc.Nasdaq: GPCRExitedPharmaceutical PreparationsSPONSORED ADS0-34,852-100.0%-$2M$1.2BQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Lyra Therapeutics IncLYRAExitedCOM NEW0-229,382-100.0%-$1M$0.1MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
FATE THERAPEUTICS INCNasdaq: FATEExitedBiological Products, (No Diagnostic Substances)COM0-345,575-100.0%-$1M$123MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Fulcrum Therapeutics, Inc.Nasdaq: FULCExitedPharmaceutical PreparationsCOM0-238,000-100.0%-$1M$283MQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
PALATIN TECHNOLOGIES INCNasdaq: PTNExitedPharmaceutical PreparationsCOM NEW0-61,945-100.0%-$1M$9MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Traws Pharma, Inc.Nasdaq: TRAWExitedPharmaceutical PreparationsCOM NEW0-421,781-100.0%-$1.0MQ2 202514 Aug 2025Q4 2024Q1 202513F, Q1 2025
ROCKET PHARMACEUTICALS, INC.Nasdaq: RCKTExitedPharmaceutical PreparationsCOM0-140,726-100.0%-$0.9M$236MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Lexeo Therapeutics, Inc.Nasdaq: LXEOExitedBiological Products, (No Diagnostic Substances)COM0-139,835-100.0%-$0.9M$244MQ4 202517 Feb 2026Q3 2024Q3 202513F, Q3 2025
Forte Biosciences Inc.ExitedCOM NEW0-68,192-100.0%-$0.9MQ3 202514 Nov 2025Q3 2024Q2 202513F, Q2 2025
NOVAVAX INCNasdaq: NVAXExitedBiological Products, (No Diagnostic Substances)COM NEW-100.0%-$0.8M$1.3BQ1 202515 May 2025Q3 2024Q4 202413F, Q4 2024
Singular Genomics Systems InExitedCOM NEW0-50,896-100.0%-$0.8MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
Kyverna Therapeutics, Inc.Nasdaq: KYTXExitedBiological Products, (No Diagnostic Substances)COM0-150,000-100.0%-$0.7M$276MQ4 202414 Feb 2025Q3 2024Q3 202413F, Q3 2024
CUMBERLAND PHARMACEUTICALS INCNasdaq: CPIXExitedPharmaceutical PreparationsCOM0-196,978-100.0%-$0.6MQ2 202614 Aug 2026Q4 2025Q1 202613F, Q1 2026
Applied Therapeutics IncExitedCOM0-860,000-100.0%-$0.4MQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Nanobiotix S.A.Nasdaq: NBTXExitedPharmaceutical PreparationsSPONSORED ADS0-105,053-100.0%-$0.4M$1.4BQ2 202514 Aug 2025Q3 2024Q1 202513F, Q1 2025
Apyx Medical CorpNasdaq: APYXExitedSurgical & Medical Instruments & ApparatusCOM0-150,000-100.0%-$0.3M$101MQ4 202517 Feb 2026Q4 2024Q3 202513F, Q3 2025
KALA BIO, Inc.Nasdaq: KALAExitedPharmaceutical PreparationsCOM NEW0-55,227-100.0%-$0.3M$2MQ3 202514 Nov 2025Q1 2025Q2 202513F, Q2 2025